3 Firms Rep ProKidney's $2.64B Go-Public SPAC Deal
Clinical-stage kidney disease treatment company ProKidney, guided by Davis Polk and Mintz, said Tuesday it will go public through a merger with a Wachtell-led special purpose acquisition vehicle at a $2.64...To view the full article, register now.
Already a subscriber? Click here to view full article